198 related articles for article (PubMed ID: 32106373)
1. MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc.
Tao L; Shu-Ling W; Jing-Bo H; Ying Z; Rong H; Xiang-Qun L; Wen-Jie C; Lin-Fu Z
Biomed Pharmacother; 2020 May; 125():109962. PubMed ID: 32106373
[TBL] [Abstract][Full Text] [Related]
2. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
[TBL] [Abstract][Full Text] [Related]
3. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.
Chen D; Huang J; Zhang K; Pan B; Chen J; De W; Wang R; Chen L
Eur J Cancer; 2014 Nov; 50(17):3050-67. PubMed ID: 25310895
[TBL] [Abstract][Full Text] [Related]
5. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
6. Emodin: One Main Ingredient of Shufeng Jiedu Capsule Reverses Chemoresistance of Lung Cancer Cells Through Inhibition of EMT.
Ying Y; Qingwu L; Mingming X; Zhenju S; Chaoyang T; Zhengang T
Cell Physiol Biochem; 2017; 42(3):1063-1072. PubMed ID: 28662514
[TBL] [Abstract][Full Text] [Related]
7. miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells.
Hu SH; Wang CH; Huang ZJ; Liu F; Xu CW; Li XL; Chen GQ
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(23):5002-5008. PubMed ID: 27981531
[TBL] [Abstract][Full Text] [Related]
8. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
Ding J; Zhao Z; Song J; Luo B; Huang L
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
10. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
11. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
12. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
13. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
14. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
15. miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.
Sun R; Liu Z; Han L; Yang Y; Wu F; Jiang Q; Zhang H; Ma R; Miao J; He K; Wang X; Zhou D; Huang C
FASEB J; 2019 Apr; 33(4):5411-5424. PubMed ID: 30698996
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
Guan X; Gu S; Yuan M; Zheng X; Wu J
Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition.
Jin Z; Guan L; Song Y; Xiang GM; Chen SX; Gao B
Eur Rev Med Pharmacol Sci; 2016; 20(6):1080-6. PubMed ID: 27049260
[TBL] [Abstract][Full Text] [Related]
19. A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer.
Yang J; Wu SP; Wang WJ; Jin ZR; Miao XB; Wu Y; Gou DM; Liu QZ; Yao KT
Exp Cell Res; 2020 Jun; 391(2):111817. PubMed ID: 32179097
[TBL] [Abstract][Full Text] [Related]
20. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells.
Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S
Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
